{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:28:20Z","timestamp":1792038500331,"version":"4.4.0"},"reference-count":127,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>\n                    The incidence of nonalcoholic fatty liver disease (NAFLD) is increasing recently and has become one of the most common clinical liver diseases. Since the pathogenesis of NAFLD has not been completely elucidated, few effective therapeutic drugs are available. As the \u201csecond genome\u201d of human body, gut microbiota plays an important role in the digestion, absorption and metabolism of food and drugs. Gut microbiota can act as an important driver to advance the occurrence and development of NAFLD, and to accelerate its progression to cirrhosis and hepatocellular carcinoma. Growing evidence has demonstrated that gut microbiota and its metabolites directly affect intestinal morphology and immune response, resulting in the abnormal activation of inflammation and intestinal endotoxemia; gut dysbiosis also causes dysfunction of gut-liver axis\n                    <jats:italic>via<\/jats:italic>\n                    alteration of bile acid metabolism pathway. Because of its composition diversity and disease-specific expression characteristics, gut microbiota holds strong promise as novel biomarkers and therapeutic targets for NAFLD. Intervening intestinal microbiota, such as antibiotic\/probiotic treatment and fecal transplantation, has been a novel strategy for preventing and treating NAFLD. In this article, we have reviewed the emerging functions and association of gut bacterial components in different stages of NAFLD progression and discussed its potential implications in NAFLD diagnosis and therapy.\n                  <\/jats:p>","DOI":"10.3389\/fcimb.2022.997018","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T01:18:37Z","timestamp":1667870317000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":214,"title":["Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications"],"prefix":"10.3389","volume":"12","author":[{"given":"Jie","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Huan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Mei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Yu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1038\/s41598-019-42059-3","article-title":"Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease","volume":"9","author":"Ahn","year":"2019","journal-title":"Sci. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/apt.12758","article-title":"Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis","volume":"39","author":"Alisi","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/S11605-021-05188-7","article-title":"The role of gut-derived lipopolysaccharides and the intestinal barrier in fatty liver diseases","volume":"26","author":"An","year":"2022","journal-title":"J. Gastrointest Surg."},{"key":"B4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/S00428-022-03330-7","article-title":"Neutrophil extracellular traps enriched with IL-1\u03b2 and IL-17A participate in the hepatic inflammatory process of patients with non-alcoholic steatohepatitis","volume":"481","author":"Arelaki","year":"2022","journal-title":"Virchows Arch."},{"key":"B5","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/SCIENCE.ABB5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1111\/1750-3841.15367","article-title":"Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial","volume":"85","author":"Behrouz","year":"2020","journal-title":"Food Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","article-title":"Nonalcoholic fatty liver disease","volume":"1","author":"Brunt","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1038\/s41598-017-02546-x","article-title":"Colonic infusions of short-chain fatty acid mixtures promote energy metabolism in overweight\/obese men: a randomized crossover trial","volume":"7","author":"Canfora","year":"2017","journal-title":"Sci. Rep."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/J.JEP.2022.115146","article-title":"Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity","volume":"292","author":"Cao","year":"2022","journal-title":"Ethnopharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/hep.29892","article-title":"Genetics of NAFLD in twins consortium. link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD","volume":"68","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/nu11030635","article-title":"The role of probiotics and prebiotics in the prevention and treatment of obesity","volume":"11","author":"Cerd\u00f3","year":"2019","journal-title":"Nutrients"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/S41467-022-29968-0","article-title":"A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease","volume":"13","author":"Cheng","year":"2022","journal-title":"Nat. Commun."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J. Med. Chem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/S12876-021-01660-5","article-title":"A randomised placebo controlled trial of VSL#3\u00ae probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease","volume":"21","author":"Chong","year":"2021","journal-title":"BMC Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2018.20046","article-title":"Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: A randomized clinical trial","volume":"321","author":"Costello","year":"2019","journal-title":"Jama"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","article-title":"Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial","volume":"115","author":"Craven","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2022.961231","article-title":"Exercise inhibits JNK pathway activation and lipotoxicity via macrophage migration inhibitory factor in nonalcoholic fatty liver disease","volume":"13","author":"Cui","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/J.EPRAC.2022.03.010","article-title":"American Association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American association for the study of liver diseases (AASLD)","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr. Pract."},{"key":"B19","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/SCIENCE.ABF3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/hep.28572","article-title":"Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach","volume":"65","author":"Del Chierico","year":"2017","journal-title":"Hepatology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.bbadis.2016.07.012","article-title":"Bile acid receptor agonists INT747 and INT777 decrease oestrogen deficiency-related postmenopausal obesity and hepatic steatosis in mice","volume":"1862","author":"de Oliveira","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.7150\/THNO.69826","article-title":"AGK regulates the progression to NASH by affecting mitochondria complex I function","volume":"12","author":"Ding","year":"2022","journal-title":"Theranostics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41586-019-1742-x","article-title":"Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease","volume":"575","author":"Duan","year":"2019","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/164_2019_238","article-title":"The pharmacology of bile acids and their receptors","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772532","article-title":"Adjunctive probiotic lactobacillus rhamnosus probio-M9 administration enhances the effect of anti-PD-1 antitumor therapy via restoring antibiotic-disrupted gut microbiota","volume":"12","author":"Gao","year":"2021","journal-title":"Front. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41401-018-0195-3","article-title":"A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters","volume":"40","author":"Ge","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/NU14132707","article-title":"Enterohepatic takeda G-protein coupled receptor 5 agonism in metabolic dysfunction-associated fatty liver disease and related glucose dysmetabolism","volume":"14","author":"Gillard","year":"2022","journal-title":"Nutrients"},{"key":"B28","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3945\/ajcn.111.020156","article-title":"Choline intake in a large cohort of patients with nonalcoholic fatty liver disease","volume":"95","author":"Guerrerio","year":"2012","journal-title":"Am. J. Clin. Nutr."},{"key":"B29","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1055\/S-0042-1748037","article-title":"Intestinal barrier dysfunction in fatty liver disease: Roles of microbiota, mucosal immune system, and bile acids","volume":"42","author":"Gupta","year":"2022","journal-title":"Semin. Liver Dis."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/J.LFS.2022.120846","article-title":"Chemotactic cytokines secreted from kupffer cells contribute to the sex-dependent susceptibility to non-alcoholic fatty liver diseases in mice","volume":"306","author":"Han","year":"2022","journal-title":"Life Sci."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2019.108794","article-title":"Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR\/LXRs-dependent manner","volume":"311","author":"Han","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/MBIO.03688-21","article-title":"Interleukin-17 weakens the NAFLD\/NASH process by facilitating intestinal barrier restoration depending on the gut microbiota","volume":"13","author":"He","year":"2022","journal-title":"mBio"},{"key":"B33","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40487-021-00171-3","article-title":"Response to PD-1-Based immunotherapy for non-small cell lung cancer altered by gut microbiota","volume":"9","author":"He","year":"2021","journal-title":"Oncol. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/hep4.1256","article-title":"FXR and TGR5 agonists ameliorate liver injury, steatosis, and inflammation after binge or prolonged alcohol feeding in mice","volume":"2","author":"Iracheta-Vellve","year":"2018","journal-title":"Hepatol. Commun."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"key":"B36","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s12072-020-10070-w","article-title":"Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders","volume":"14","author":"Karpen","year":"2020","journal-title":"Hepatol. Int."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/J.JCEH.2022.01.006","article-title":"Demonstration of gut-barrier dysfunction in early stages of non-alcoholic fatty liver disease: A proof-Of-Concept study","volume":"12","author":"Kaushal","year":"2022","journal-title":"Clin. Exp. Hepatol."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-037961","article-title":"Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease","volume":"10","author":"Kessoku","year":"2020","journal-title":"BMJ Open"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/biom10101445","article-title":"Metabolic functions of G protein-coupled receptors in hepatocytes-potential applications for diabetes and NAFLD","volume":"10","author":"Kimura","year":"2020","journal-title":"Biomolecules"},{"key":"B40","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/hep.25731","article-title":"Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial","volume":"56","author":"Le","year":"2012","journal-title":"Hepatology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s10620-020-06100-0","article-title":"Fecal microbiota transplantation for chronic liver diseases: Current understanding and future direction","volume":"65","author":"Lechner","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","article-title":"Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/FCIMB.2022.827516","article-title":"Amelioration of non-alcoholic steatohepatitis by atractylodes macrocephala polysaccharide, chlorogenic acid, and geniposide combination is associated with reducing endotoxin gut leakage","volume":"12","author":"Leng","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/S41396-022-01292-X","article-title":"Ecological memory of prior nutrient exposure in the human gut microbiome","volume":"10","author":"Letourneau","year":"2022","journal-title":"ISME J."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abk0855","article-title":"Risk assessment with gut microbiome and metabolite markers in NAFLD development","volume":"14","author":"Leung","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.jceh.2021.11.011","article-title":"The effects of pathogen-associated molecular patterns on peripheral blood monocytes in patients with non-alcoholic fatty liver disease","volume":"12","author":"Li","year":"2022","journal-title":"Clin. Exp. Hepatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41522-021-00205-8","article-title":"Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-n-oxide production via manipulating the gut microbiome","volume":"7","author":"Li","year":"2021","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1007\/s00394-020-02431-w","article-title":"A bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty liver disease positively: by changing gut barrier","volume":"60","author":"Liu","year":"2021","journal-title":"Eur. J. Nutr."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202100939R","article-title":"\"Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases.\"","volume":"35","author":"Liu","year":"2021","journal-title":"FASEB J."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Lonardo","year":"2016","journal-title":"Hepatology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.cmet.2019.08.002","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"30","author":"Loomba","year":"2019","journal-title":"Cell Metab."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/srep37589","article-title":"Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating G protein-coupled receptors and gut microbiota","volume":"6","author":"Lu","year":"2016","journal-title":"Sci. Rep."},{"key":"B53","doi-asserted-by":"publisher","first-page":"324","DOI":"10.2337\/db18-0315","article-title":"TGR5 activation promotes stimulus-secretion coupling of pancreatic \u03b2-cells via a PKA-dependent pathway","volume":"68","author":"Maczewsky","year":"2019","journal-title":"Diabetes"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan5931","article-title":"Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells","volume":"360","author":"Ma","year":"2018","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBALIP.2022.159218","article-title":"Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1\/FXR signaling","volume":"1867","author":"Marchian\u00f2","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"B56","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/S41591-022-01698-2","article-title":"Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1","author":"McCulloch","year":"2022","journal-title":"Nat. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"11761","DOI":"10.1074\/jbc.M112.446575","article-title":"Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease","volume":"288","author":"McMahan","year":"2013","journal-title":"Biol. Chem."},{"key":"B58","doi-asserted-by":"publisher","first-page":"220121","DOI":"10.1183\/16000617.0121-2022","article-title":"Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations","volume":"31","author":"Mitropoulou","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/nu13093192","article-title":"The effect of probiotics (MCP\u00ae BCMC\u00ae strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease","volume":"13","author":"Mohamad Nor","year":"2021","journal-title":"Nutrients"},{"key":"B60","first-page":"44","article-title":"Fecal microbiota in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review","volume":"23","author":"Mohammadi","year":"2020","journal-title":"Arch. Iran Med. ."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development","volume":"71","author":"Mouries","year":"2019","journal-title":"Hepatol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/MEDICINA58060761","article-title":"An update on the chemokine system in the development of NAFLD","volume":"58","author":"Nagata","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154844","article-title":"Intestine-liver crosstalk in type 2 diabetes and non-alcoholic fatty liver disease","volume":"123","author":"Nawrot","year":"2021","journal-title":"Metabolism"},{"key":"B65","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"NASH clinical research network Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22083899","article-title":"Nonalcoholic fatty liver disease: Focus on new biomarkers and lifestyle interventions","volume":"22","author":"Notarnicola","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cmet.2020.06.005","article-title":"A universal gut-Microbiome-Derived signature predicts cirrhosis","volume":"32","author":"Oh","year":"2020","journal-title":"Cell Metab."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57080822","article-title":"Phytotherapy as multi-hit therapy to confront the multiple pathophysiology in non-alcoholic fatty liver disease: A systematic review of experimental interventions","volume":"57","author":"Ore","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"B69","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/iub.1960","article-title":"IL-17A-mediated ERK1\/2\/p65 signaling pathway is associated with cell apoptosis after non-alcoholic steatohepatitis","volume":"71","author":"Pan","year":"2019","journal-title":"IUBMB Life."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2022.111678","article-title":"Recent advances on FXR-targeting therapeutics","volume":"552","author":"Panzitt","year":"2022","journal-title":"Mol. Cell Endocrinol."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156334","article-title":"Promotion of intestinal epithelial cell turnover by commensal bacteria: Role of short-chain fatty acids","volume":"11","author":"Park","year":"2016","journal-title":"PloS One"},{"key":"B72","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: A phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/imm.13028","article-title":"Interleukin-17\/interleukin-17 receptor axis elicits intestinal neutrophil migration, restrains gut dysbiosis and lipopolysaccharide translocation in high-fat diet-induced metabolic syndrome model","volume":"156","author":"P\u00e9rez","year":"2019","journal-title":"Immunology"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/diseases6040086","article-title":"The role of vitamin e in the treatment of NAFLD","volume":"6","author":"Perumpail","year":"2018","journal-title":"Diseases"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.14309\/CTG.0000000000000466","article-title":"Relationship between hepatic gene expression, intestinal microbiota, and inferred functional metagenomic analysis in NAFLD","volume":"13","author":"Pettinelli","year":"2022","journal-title":"Clin. Transl. Gastroenterol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.cgh.2016.10.029","article-title":"Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: A pilot study","volume":"15","author":"Philips","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1053\/j.gastro.2020.07.036","article-title":"FXR isoforms control different metabolic functions in liver cells via binding to specific DNA motifs","volume":"159","author":"Ramos Pittol","year":"2020","journal-title":"Gastroenterology"},{"key":"B79","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J. Hepatol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.1080\/10408398.2021.1895064","article-title":"Recent advances in the therapeutic application of short-chain fatty acids (SCFAs): An updated review","volume":"62","author":"Rauf","year":"2022","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS23169016","article-title":"Role of vitamin d in liver disease and complications of advanced chronic liver disease","volume":"23","author":"Ravaioli","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197097","article-title":"Prolonged lipid accumulation in cultured primary human hepatocytes rather leads to ER stress than oxidative stress","volume":"21","author":"Rennert","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/07315724.2015.1031355","article-title":"Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: A double-blind randomized clinical trial","volume":"35","author":"Sepideh","year":"2016","journal-title":"J. Am. Coll. Nutr."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/J.LFS.2022.120956","article-title":"Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms","volume":"308","author":"Shaaban","year":"2022","journal-title":"Life Sci."},{"key":"B86","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ajcn\/nqz042","article-title":"Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"110","author":"Sharpton","year":"2019","journal-title":"Am. J. Clin. Nutr."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.bbadis.2017.01.027","article-title":"Interleukin-17A exacerbates high-fat diet-induced hepatic steatosis by inhibiting fatty acid \u03b2-oxidation","volume":"1863","author":"Shen","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.BBRC.2022.01.060","article-title":"Changes of flavin-containing monooxygenases and trimethylamine-n-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine","volume":"594","author":"Shi","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B89","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/J.CLLC.2021.10.012","article-title":"A multicenter, randomized phase III study comparing platinum combination chemotherapy plus pembrolizumab with platinum combination chemotherapy plus nivolumab and ipilimumab for treatment-naive advanced non-small cell lung cancer without driver gene alterations: JCOG2007 (NIPPON study)","volume":"23","author":"Shiraishi","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.cell.2018.09.004","article-title":"Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer","volume":"175","author":"Singh","year":"2018","journal-title":"Cell"},{"key":"B91","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4161\/gmic.28203","article-title":"Association of germ-free mice with a simplified human intestinal microbiota results in a shortened intestine","volume":"5","author":"Slezak","year":"2014","journal-title":"Gut Microbes"},{"key":"B92","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40168-020-0792-5","article-title":"Fecal microbiota transplantation to maintain remission in crohn's disease: a pilot randomized controlled study","volume":"8","author":"Sokol","year":"2020","journal-title":"Microbiome"},{"key":"B93","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1038\/s41467-021-25213-2","article-title":"Gut microbiome-mediated metabolism effects on immunity in rural and urban African populations","volume":"12","author":"Stra\u017ear","year":"2021","journal-title":"Nat. Commun."},{"key":"B94","doi-asserted-by":"publisher","first-page":"16796","DOI":"10.1038\/s41598-019-52980-2","article-title":"High-fat diet-mediated dysbiosis exacerbates NSAID-induced small intestinal damage through the induction of interleukin-17A","volume":"9","author":"Sugimura","year":"2019","journal-title":"Sci. Rep."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1751989","article-title":"Serum fibroblast growth factor 19 and total bile acid concentrations are potential biomarkers of hepatocellular carcinoma in patients with type 2 diabetes mellitus","volume":"2020","author":"Sun","year":"2020","journal-title":"BioMed. Res. Int."},{"key":"B96","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3350\/cmh.2022.0040","article-title":"Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs","volume":"28","author":"Takamura","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201900257","article-title":"Trimethylamine n-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid X receptor signaling in nonalcoholic fatty liver disease","volume":"63","author":"Tan","year":"2019","journal-title":"Mol. Nutr. Food Res."},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0214-1","article-title":"Is serum interleukin-17 associated with early atherosclerosis in obese patients","volume":"12","author":"Tarantino","year":"2014","journal-title":"J. Transl. Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/S00281-022-00910-2","article-title":"TNF in the liver: targeting a central player in inflammation","volume":"44","author":"Tiegs","year":"2022","journal-title":"Semin. Immunopathol."},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/FCVM.2021.777131","article-title":"Statins in non-alcoholic steatohepatitis","volume":"8","author":"Torres-Pe\u00f1a","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00508-020-01735","article-title":"Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease","volume":"133","author":"Traussnigg","year":"2021","journal-title":"Wien. Klin. Wochenschr."},{"key":"B102","doi-asserted-by":"publisher","first-page":"5725","DOI":"10.1038\/s41467-022-33294-w","article-title":"Bacteriophage-antibiotic combination therapy against extensively drug-resistant pseudomonas aeruginosa infection to allow liver transplantation in a toddler","volume":"13","author":"Van Nieuwenhuyse","year":"2022","journal-title":"Nat. Commun."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2020.104009","article-title":"Contribution of endotoxin to Th17 bias in patients with non-alcoholic steatohepatitis","volume":"142","author":"Wang","year":"2020","journal-title":"Microb. Pathog."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.667768","article-title":"Interleukin-17-Producing CD4+ T cells promote inflammatory response and foster disease progression in hyperlipidemic patients and atherosclerotic mice","volume":"8","author":"Wang","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jhep.2017.05.007","article-title":"Targeting the gut-liver axis in liver disease","volume":"67","author":"Wiest","year":"2017","journal-title":"Hepatol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.clinthera.2021.01.007","article-title":"Nonalcoholic fatty liver disease: A global perspective","volume":"43","author":"Wong","year":"2021","journal-title":"Clin. Ther."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.3390\/nu13082878","article-title":"Potential benefits of probiotics and prebiotics for coronary heart disease and stroke","volume":"13","author":"Wu","year":"2021","journal-title":"Nutrients"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1002\/IJC.34118","article-title":"Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma","volume":"151","author":"Wu","year":"2022","journal-title":"Int. J. Cancer"},{"key":"B109","first-page":"678","article-title":"Effects of probiotics combined with enteral nutrition on immune function and inflammatory response in postoperative patients with gastric cancer","volume":"23","author":"Xie","year":"2018","journal-title":"buon"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/FCIMB.2022.759306","article-title":"Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: A randomized clinical trial","volume":"12","author":"Xue","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.3748\/wjg.v27.i24.3609","article-title":"Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis","volume":"27","author":"Yang","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s12072-010-9202-6","article-title":"Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease","volume":"4","author":"Yang","year":"2010","journal-title":"Hepatol. Int."},{"key":"B113","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1111\/liv.14916","article-title":"Effects of lifestyle interventions on epigenetic signatures of liver fat: Central randomized controlled trial","volume":"41","author":"Yaskolka Meir","year":"2021","journal-title":"Liver Int."},{"key":"B114","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"B115","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cmet.2019.08.018","article-title":"Fatty liver disease caused by high-Alcohol-Producing klebsiella pneumoniae","volume":"30","author":"Yuan","year":"2019","journal-title":"Cell Metab."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/FCIMB.2022.855008","article-title":"Schisantherin a alleviates non-alcoholic fatty liver disease by restoring intestinal barrier function","volume":"12","author":"Yu","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2019.108336","article-title":"Advanced liver steatosis accompanies an increase in hepatic inflammation, colonic, secondary bile acids and Lactobacillaceae\/Lachnospiraceae bacteria in C57BL\/6 mice fed a high-fat diet","volume":"78","author":"Zeng","year":"2020","journal-title":"Nutr. Biochem."},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2022.2046246","article-title":"Lacticaseibacillus paracasei sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice","volume":"14","author":"Zhang","year":"2022","journal-title":"Gut Microbes"},{"key":"B119","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/J.FREERADBIOMED.2022.07.018","article-title":"CREBH alleviates mitochondrial oxidative stress through SIRT3 mediating deacetylation of MnSOD and suppression of Nlrp3 inflammasome in NASH","volume":"190","author":"Zhang","year":"2022","journal-title":"Free Radic. Biol. Med."},{"key":"B120","doi-asserted-by":"publisher","first-page":"10023","DOI":"10.1039\/D2FO01747D","article-title":"Lactobacillus kefiranofaciens ZW18 from kefir enhances the anti-tumor effect of anti-programmed cell death 1 (PD-1) immunotherapy by modulating the gut microbiota","volume":"13","author":"Zhao","year":"2022","journal-title":"Food Funct."},{"key":"B121","doi-asserted-by":"publisher","first-page":"210","DOI":"10.14715\/cmb\/2021.67.5.29","article-title":"Effects of endoplasmic reticulum stress, liver function, insulin resistance and vascular endothelial function in patients with nonalcoholic fatty liver disease","volume":"67","author":"Zheng","year":"2022","journal-title":"Cell Mol. Biol. (Noisy-le-grand)"},{"key":"B122","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1038\/s41380-020-0744-2","article-title":"The gut microbiome modulates gut-brain axis glycerophospholipid metabolism in a region-specific manner in a nonhuman primate model of depression","volume":"26","author":"Zheng","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0183-1","article-title":"Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression","volume":"50","author":"Zhou","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41598-017-01751-y","article-title":"Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological features of NAFLD from 1999 to 2018 in China","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology"},{"key":"B126","doi-asserted-by":"publisher","first-page":"64","DOI":"10.14715\/cmb\/2022.68.2.10","article-title":"Effects of clostridium butyricum capsules combined with rosuvastatin on intestinal flora, lipid metabolism, liver function and inflammation in NAFLD patients","volume":"68","author":"Zhu","year":"2022","journal-title":"Cell Mol. Biol. (Noisy-le-grand)"},{"key":"B127","doi-asserted-by":"publisher","first-page":"E346","DOI":"10.1152\/ajpendo.00485.2015","article-title":"Bile acids induce uncoupling protein 1-dependent thermogenesis and stimulate energy expenditure at thermoneutrality in mice","volume":"310","author":"Zietak","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.997018\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T01:18:42Z","timestamp":1667870322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.997018\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":127,"alternative-id":["10.3389\/fcimb.2022.997018"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.997018","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"article-number":"997018"}}